Therapeutic vaccine for Genital herpes simplex virus-2 infection: Findings from a randomized trial

David I. Bernstein, Anna Wald, Terri Warren, Kenneth Fife, Stephen Tyring, Patricia Lee, Nick Van Wagoner, Amalia Magaret, Jessica B. Flechtner, Sybil Tasker, Jason Chan, Amy Morris, Seth Hetherington

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Genital herpes simplex virus type 2 (HSV-2) infection causes recurrent lesions and frequent viral shedding. GEN-003 is a candidate therapeutic vaccine containing HSV-2 gD2ΔTMR and ICP4.2, and Matrix-M2 adjuvant. Methods: Persons with genital herpes were randomized into 3 dose cohorts to receive 3 intramuscular doses 21 days apart of 10 μg, 30 μg, or 100 μg of GEN-003, antigens without adjuvant, or placebo. Participants obtained genital swab specimens twice daily for HSV-2 detection and monitored genital lesions for 28-day periods at baseline and at intervals after the last dose. Results. One hundred and thirty-four persons received all 3 doses. Reactogenicity was associated with adjuvant but not with antigen dose or dose number. No serious adverse events were attributed to GEN-003. Compared with baseline, genital HSV-2 shedding rates immediately after dosing were reduced with GEN-003 (from 13.4% to 6.4% for 30 μg [P <.001] and from 15.0% to 10.3% for 100 μg [P μ.001]). Lesion rates were also significantly (P μ.01) reduced immediately following immunization with 30 μg or 100 μg of GEN-003. GEN-003 elicited increases in antigen binding, virus neutralizing antibody, and T-cell responses. Conclusions. GEN-003 had an acceptable safety profile and stimulated humoral and cellular immune responses. GEN-003 at doses of 30 μg and 100 μg reduced genital HSV shedding and lesion rates.

Original languageEnglish (US)
Pages (from-to)856-864
Number of pages9
JournalJournal of Infectious Diseases
Volume215
Issue number6
DOIs
StatePublished - Mar 15 2017

Fingerprint

Herpes Genitalis
Human Herpesvirus 2
Virus Diseases
Vaccines
Virus Shedding
Antigens
Virus Attachment
Therapeutics
Humoral Immunity
Neutralizing Antibodies
Cellular Immunity
Immunization
Placebos
T-Lymphocytes
Safety

Keywords

  • GEN-003
  • Genital herpes
  • Herpes simplex virus type 2 infection
  • Immunotherapy
  • Therapeutic vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Therapeutic vaccine for Genital herpes simplex virus-2 infection : Findings from a randomized trial. / Bernstein, David I.; Wald, Anna; Warren, Terri; Fife, Kenneth; Tyring, Stephen; Lee, Patricia; Van Wagoner, Nick; Magaret, Amalia; Flechtner, Jessica B.; Tasker, Sybil; Chan, Jason; Morris, Amy; Hetherington, Seth.

In: Journal of Infectious Diseases, Vol. 215, No. 6, 15.03.2017, p. 856-864.

Research output: Contribution to journalArticle

Bernstein, DI, Wald, A, Warren, T, Fife, K, Tyring, S, Lee, P, Van Wagoner, N, Magaret, A, Flechtner, JB, Tasker, S, Chan, J, Morris, A & Hetherington, S 2017, 'Therapeutic vaccine for Genital herpes simplex virus-2 infection: Findings from a randomized trial', Journal of Infectious Diseases, vol. 215, no. 6, pp. 856-864. https://doi.org/10.1093/infdis/jix004
Bernstein, David I. ; Wald, Anna ; Warren, Terri ; Fife, Kenneth ; Tyring, Stephen ; Lee, Patricia ; Van Wagoner, Nick ; Magaret, Amalia ; Flechtner, Jessica B. ; Tasker, Sybil ; Chan, Jason ; Morris, Amy ; Hetherington, Seth. / Therapeutic vaccine for Genital herpes simplex virus-2 infection : Findings from a randomized trial. In: Journal of Infectious Diseases. 2017 ; Vol. 215, No. 6. pp. 856-864.
@article{a55d11f29db6407fa05372bcef90b0ed,
title = "Therapeutic vaccine for Genital herpes simplex virus-2 infection: Findings from a randomized trial",
abstract = "Background: Genital herpes simplex virus type 2 (HSV-2) infection causes recurrent lesions and frequent viral shedding. GEN-003 is a candidate therapeutic vaccine containing HSV-2 gD2ΔTMR and ICP4.2, and Matrix-M2 adjuvant. Methods: Persons with genital herpes were randomized into 3 dose cohorts to receive 3 intramuscular doses 21 days apart of 10 μg, 30 μg, or 100 μg of GEN-003, antigens without adjuvant, or placebo. Participants obtained genital swab specimens twice daily for HSV-2 detection and monitored genital lesions for 28-day periods at baseline and at intervals after the last dose. Results. One hundred and thirty-four persons received all 3 doses. Reactogenicity was associated with adjuvant but not with antigen dose or dose number. No serious adverse events were attributed to GEN-003. Compared with baseline, genital HSV-2 shedding rates immediately after dosing were reduced with GEN-003 (from 13.4{\%} to 6.4{\%} for 30 μg [P <.001] and from 15.0{\%} to 10.3{\%} for 100 μg [P μ.001]). Lesion rates were also significantly (P μ.01) reduced immediately following immunization with 30 μg or 100 μg of GEN-003. GEN-003 elicited increases in antigen binding, virus neutralizing antibody, and T-cell responses. Conclusions. GEN-003 had an acceptable safety profile and stimulated humoral and cellular immune responses. GEN-003 at doses of 30 μg and 100 μg reduced genital HSV shedding and lesion rates.",
keywords = "GEN-003, Genital herpes, Herpes simplex virus type 2 infection, Immunotherapy, Therapeutic vaccine",
author = "Bernstein, {David I.} and Anna Wald and Terri Warren and Kenneth Fife and Stephen Tyring and Patricia Lee and {Van Wagoner}, Nick and Amalia Magaret and Flechtner, {Jessica B.} and Sybil Tasker and Jason Chan and Amy Morris and Seth Hetherington",
year = "2017",
month = "3",
day = "15",
doi = "10.1093/infdis/jix004",
language = "English (US)",
volume = "215",
pages = "856--864",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Therapeutic vaccine for Genital herpes simplex virus-2 infection

T2 - Findings from a randomized trial

AU - Bernstein, David I.

AU - Wald, Anna

AU - Warren, Terri

AU - Fife, Kenneth

AU - Tyring, Stephen

AU - Lee, Patricia

AU - Van Wagoner, Nick

AU - Magaret, Amalia

AU - Flechtner, Jessica B.

AU - Tasker, Sybil

AU - Chan, Jason

AU - Morris, Amy

AU - Hetherington, Seth

PY - 2017/3/15

Y1 - 2017/3/15

N2 - Background: Genital herpes simplex virus type 2 (HSV-2) infection causes recurrent lesions and frequent viral shedding. GEN-003 is a candidate therapeutic vaccine containing HSV-2 gD2ΔTMR and ICP4.2, and Matrix-M2 adjuvant. Methods: Persons with genital herpes were randomized into 3 dose cohorts to receive 3 intramuscular doses 21 days apart of 10 μg, 30 μg, or 100 μg of GEN-003, antigens without adjuvant, or placebo. Participants obtained genital swab specimens twice daily for HSV-2 detection and monitored genital lesions for 28-day periods at baseline and at intervals after the last dose. Results. One hundred and thirty-four persons received all 3 doses. Reactogenicity was associated with adjuvant but not with antigen dose or dose number. No serious adverse events were attributed to GEN-003. Compared with baseline, genital HSV-2 shedding rates immediately after dosing were reduced with GEN-003 (from 13.4% to 6.4% for 30 μg [P <.001] and from 15.0% to 10.3% for 100 μg [P μ.001]). Lesion rates were also significantly (P μ.01) reduced immediately following immunization with 30 μg or 100 μg of GEN-003. GEN-003 elicited increases in antigen binding, virus neutralizing antibody, and T-cell responses. Conclusions. GEN-003 had an acceptable safety profile and stimulated humoral and cellular immune responses. GEN-003 at doses of 30 μg and 100 μg reduced genital HSV shedding and lesion rates.

AB - Background: Genital herpes simplex virus type 2 (HSV-2) infection causes recurrent lesions and frequent viral shedding. GEN-003 is a candidate therapeutic vaccine containing HSV-2 gD2ΔTMR and ICP4.2, and Matrix-M2 adjuvant. Methods: Persons with genital herpes were randomized into 3 dose cohorts to receive 3 intramuscular doses 21 days apart of 10 μg, 30 μg, or 100 μg of GEN-003, antigens without adjuvant, or placebo. Participants obtained genital swab specimens twice daily for HSV-2 detection and monitored genital lesions for 28-day periods at baseline and at intervals after the last dose. Results. One hundred and thirty-four persons received all 3 doses. Reactogenicity was associated with adjuvant but not with antigen dose or dose number. No serious adverse events were attributed to GEN-003. Compared with baseline, genital HSV-2 shedding rates immediately after dosing were reduced with GEN-003 (from 13.4% to 6.4% for 30 μg [P <.001] and from 15.0% to 10.3% for 100 μg [P μ.001]). Lesion rates were also significantly (P μ.01) reduced immediately following immunization with 30 μg or 100 μg of GEN-003. GEN-003 elicited increases in antigen binding, virus neutralizing antibody, and T-cell responses. Conclusions. GEN-003 had an acceptable safety profile and stimulated humoral and cellular immune responses. GEN-003 at doses of 30 μg and 100 μg reduced genital HSV shedding and lesion rates.

KW - GEN-003

KW - Genital herpes

KW - Herpes simplex virus type 2 infection

KW - Immunotherapy

KW - Therapeutic vaccine

UR - http://www.scopus.com/inward/record.url?scp=85019739151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019739151&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix004

DO - 10.1093/infdis/jix004

M3 - Article

C2 - 28329211

AN - SCOPUS:85019739151

VL - 215

SP - 856

EP - 864

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -